Colorectal Cancer Management

Colorectal cancer is one of the most prevalent cancers in North America. It strikes approximately 165,000 people and causes nearly 60,000 deaths each year in the United States and Canada. With an overall 5-year survival rate of 65%, colorectal cancer is the second leading cause of cancer death, accounting for almost 9% of all cancer deaths.

Colorectal cancer develops slowly as premalignant polyps that occur on the bowel wall and eventually increase in size and become cancerous. Colorectal cancer is curable if caught early enough, and proper staging is important to determine the extent of cancer involvement and if therapy is warranted.

DiagnoCure’s pipeline currently includes two focal areas for colorectal cancer, one involving the marker Guanylyl Cyclase C and the other surrounding Shc proteins.  This section of the website takes you through several topics related to the Company’s investments in colorectal cancer: